




CORRIGENDUM

Corrigendum to: Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study

G. Rojas-Marte ^{1,2}, M. Khalid¹, O. Mukhtar³, A. T. Hashmi ¹, M. A. Waheed⁴, S. Ehrlich⁴, A. Aslam⁴, S. Siddiqui¹, G. Agarwal¹, Y. Malyshev¹, C. Henriquez-Felipe¹, D. Sharma⁴, S. Sharma ⁴, N. Chukwuka⁴, D. C. Rodriguez¹, S. Alliu¹, J. Le¹ and J. Shani¹

From the ¹Department of Cardiology, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA, ²Department of Cardiology, Staten Island University Hospital-Northwell Health, 475 Seaview Avenue, Staten Island, NY 10305, USA, ³Department of Pulmonology, Interfaith Medical Center, 1545 Atlantic Avenue, Brooklyn, NY 11213, USA and ⁴Department of Internal Medicine, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA

Address correspondence to G.R. Rojas-Marte, Zucker School of Medicine at Hofstra/Northwell, Department of Cardiology, Maimonides Medical Center, 4802 10th Ave, Brooklyn, NY, USA. email: grmarte@maimonidesmed.org

QJM: An International Journal of Medicine 2020; 00:546–550.
<https://doi.org/10.1093/qjmed/hcaa206>

The original version of this article contained minor errors in the abstract and Table 2. Additionally, the author, G. Rojas-Marte was written with an incorrect middle initial. These mistakes have now been corrected.